Literature DB >> 17126318

Activators of potassium M currents have anticonvulsant actions in two rat models of encephalitis.

Marylou V Solbrig1, Russell Adrian, Steven L Wechsler, George F Koob.   

Abstract

Opioid systems in hippocampus regulate excitability and kappa opioids have a role in anticonvulsant protection, but their mechanisms of action are incompletely understood. We examined the ability of opioid and nonopioid agents with overlapping ionic mechanisms and actions similar to kappa opioid agonists, to block seizures in rat models of encephalitis due to Borna Disease virus and Herpes Simplex Virus Type-1. Naltrindole, a delta antagonist and thus a kappa opioid sparing agent, (10 mg/kg s.c.) blocked spontaneous and naloxone (opioid antagonist)-induced seizures in the models, but produced somatic signs similar to opioid withdrawal. Given that delta antagonists as well as kappa opioid agonists in hippocampus enhance potassium M currents (I(M)), we tested the effect of the I(M) augmenter flupirtine. Flupirtine (20 mg/kg i.p.) prevented seizures in Borna and herpes infected rats, without signs of withdrawal, hypotonia or sedation. The results support the efficacy of opioid and nonopioid drugs in modulating naloxone-induced seizures in critical illness due to viral encephalitis and by analogy, opioid withdrawal seizures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17126318      PMCID: PMC2981072          DOI: 10.1016/j.ejphar.2006.10.025

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

1.  Tardive dyskinetic syndrome in rats infected with Borna disease virus.

Authors:  M V Solbrig; G F Koob; J H Fallon; W I Lipkin
Journal:  Neurobiol Dis       Date:  1994-12       Impact factor: 5.996

2.  A potassium channel mutation in neonatal human epilepsy.

Authors:  C Biervert; B C Schroeder; C Kubisch; S F Berkovic; P Propping; T J Jentsch; O K Steinlein
Journal:  Science       Date:  1998-01-16       Impact factor: 47.728

3.  A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena.

Authors:  Marylou V Solbrig; Russell Adrian; Janie Baratta; Daniele Piomelli; Andrea Giuffrida
Journal:  Exp Neurol       Date:  2005-08       Impact factor: 5.330

4.  Electrical stimulation of substantia nigra pars reticulata is anticonvulsant in adult and young male rats.

Authors:  Libor Velísek; Jana Velísková; Solomon L Moshé
Journal:  Exp Neurol       Date:  2002-01       Impact factor: 5.330

5.  Low-voltage activity in EEG during acute phase of encephalitis predicts unfavorable neurological outcome.

Authors:  Machiko Hosoya; Hideo Ushiku; Hirokazu Arakawa; Akihiro Morikawa
Journal:  Brain Dev       Date:  2002-04       Impact factor: 1.961

6.  A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns.

Authors:  N A Singh; C Charlier; D Stauffer; B R DuPont; R J Leach; R Melis; G M Ronen; I Bjerre; T Quattlebaum; J V Murphy; M L McHarg; D Gagnon; T O Rosales; A Peiffer; V E Anderson; M Leppert
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

Review 7.  Opiate treatment for opiate withdrawal in newborn infants.

Authors:  D A Osborn; H E Jeffery; M Cole
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

8.  Viral risk factor for seizures: pathobiology of dynorphin in herpes simplex viral (HSV-1) seizures in an animal model.

Authors:  Marylou V Solbrig; Russell Adrian; Daniel Y Chang; Guey-Chuen Perng
Journal:  Neurobiol Dis       Date:  2006-07-14       Impact factor: 5.996

9.  Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism.

Authors:  S G Madamba; P Schweitzer; G R Siggins
Journal:  J Neurophysiol       Date:  1999-10       Impact factor: 2.714

10.  Kappa opioid control of seizures produced by a virus in an animal model.

Authors:  Marylou V Solbrig; Russell Adrian; Janie Baratta; Julie C Lauterborn; George F Koob
Journal:  Brain       Date:  2006-01-06       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.